Severens J L, Prins J B, van der Wilt G J, van der Meer J W M, Bleijenberg G
Department of Medical Technology Assessment, University Medical Centre Nijmegen, The Netherlands.
QJM. 2004 Mar;97(3):153-61. doi: 10.1093/qjmed/hch029.
There is some evidence that cognitive behaviour therapy (CBT) is efficacious in chronic fatigue syndrome (CFS), but little data on its cost-effectiveness.
Prospective economic analysis alongside a randomized clinical trial.
CFS patients were randomly assigned to CBT, guided support groups (SG), or the 'natural course' (NC, no protocol-based interventions). Patients were treated for 8 months and followed-up for another 6 months. Costs per patient showing clinically significant improvement, based on the CIS fatigue scale, and costs per quality-adjusted life year, were determined for a time period of 14 months.
Data were available for 171 patients at 8 months and for 128 at 14 months. At 8 and 14 months, the percentages of improved patients were 31% and 27% for CBT, 9% and 11% for SG, and 12% and 20% for NC. Mean QALYs gained at 14 months were, for CBT, SG and NC, respectively, 0.0737, -0.0018 and 0.0458. CBT and SG mean treatment costs were euro1490 and euro424. Other medical costs for CBT, SG, and NC, respectively, were euro324, euro623 and euro412 for the first period, and euro232, euro561 and euro378 for the second period. Non-medical costs for these periods for CBT, SG and NC were euro262, euro550, euro427 and euro226, euro439, euro287, respectively. Productivity costs were considerable, but not significantly different between groups.
CBT was less costly and more effective than SG. Compared to NC, the baseline incremental cost-effectiveness of CBT was euro20 516 per CFS patient showing clinically significant improvement, and euro21 375 per QALY. The bootstrap ratios showed considerable uncertainty regarding the results. Future research should focus on productivity costs, and follow patients prospectively over a longer period.
有证据表明认知行为疗法(CBT)对慢性疲劳综合征(CFS)有效,但关于其成本效益的数据较少。
前瞻性经济分析与随机临床试验同时进行。
将CFS患者随机分配至CBT组、引导支持组(SG)或“自然病程”组(NC,不进行基于方案的干预)。患者接受8个月治疗,并随访6个月。根据CIS疲劳量表确定每位显示出临床显著改善的患者的成本,以及每质量调整生命年的成本,为期14个月。
8个月时有171例患者的数据可用,14个月时有128例患者的数据可用。在8个月和14个月时,CBT组改善患者的百分比分别为31%和27%,SG组为9%和11%,NC组为12%和20%。在14个月时,CBT组、SG组和NC组分别获得的平均质量调整生命年为0.0737、-0.0018和0.0458。CBT组和SG组的平均治疗成本分别为1490欧元和424欧元。CBT组、SG组和NC组在第一阶段的其他医疗成本分别为324欧元、623欧元和412欧元,在第二阶段分别为232欧元、561欧元和378欧元。这些阶段CBT组、SG组和NC组的非医疗成本分别为262欧元、550欧元、427欧元和226欧元、439欧元、287欧元。生产力成本相当可观,但各组之间无显著差异。
CBT比SG成本更低且更有效。与NC组相比,CBT组每例显示出临床显著改善的CFS患者的基线增量成本效益为20516欧元,每质量调整生命年为21375欧元。自举比率显示结果存在相当大的不确定性。未来的研究应关注生产力成本,并对患者进行更长时间的前瞻性随访。